Clinical Trial

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Study acronym: EDGE-Gastric
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Protocol Amendment History 1 change
notable Trial sites reduced: 49 -> 42 locations 2026-04-30
Trial Details
NCT Number NCT05329766
Lead Sponsor Arcus Biosciences, Inc.
Collaborators: Gilead Sciences
Conditions Gastrointestinal Tract Malignancies
Enrollment 332 participants
Start Date 2022-06-10
Primary Completion 2027-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-29